Clomid – Clomiphene Citrate

Description

Clomiphene Citrate 50mg: Selective Oestrogen Receptor Modulator (SERM) for Endocrine Research

Clomiphene Citrate is a synthetic, non-steroidal selective oestrogen receptor modulator (SERM) with a well-established history in reproductive endocrinology research. It exerts tissue-selective oestrogen receptor antagonism, primarily at the level of the hypothalamus and pituitary gland, where it competitively inhibits oestrogen receptor binding and disrupts normal negative feedback signalling along the hypothalamic-pituitary-gonadal (HPG) axis.

Originally investigated as a fertility compound in anovulatory models, Clomiphene Citrate has since become a subject of broader endocrine research – including studies on male hypogonadism, luteinising hormone (LH) secretion, and gonadotropin-dependent testosterone regulation. Its dual agonist-antagonist receptor profile makes it a distinct SERM within the context of hormonal axis research.

Product Summary

Mechanism of Action

Clomiphene Citrate operates as a competitive antagonist at oestrogen receptors located in the hypothalamus. Under normal physiological conditions, circulating oestrogen binds to these receptors and suppresses the pulsatile release of gonadotropin-releasing hormone (GnRH). By occupying these receptors without activating them, Clomiphene Citrate blocks this negative feedback loop.

The resulting reduction in negative feedback stimulates increased GnRH secretion from the hypothalamus, which in turn drives elevated release of luteinising hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary. In gonadal tissue, elevated LH stimulates Leydig cell testosterone synthesis, while elevated FSH supports spermatogenic function in male reproductive models.

Clomiphene Citrate exists as a racemic mixture of two geometric isomers – enclomiphene (trans) and zuclomiphene (cis) – which differ in their receptor binding affinity and biological half-life, a distinction that has attracted specific investigation in male hypogonadism research.

In Vivo Research Findings

• Increased LH and FSH secretion via hypothalamic oestrogen receptor blockade and disruption of negative HPG axis feedback
• Elevated endogenous testosterone levels observed in male hypogonadism models, including studies comparing outcomes to exogenous testosterone replacement
• Preserved spermatogenesis in male fertility research, in contrast to suppression observed with exogenous androgen administration
• Ovulation induction in anovulatory female models – the primary application in reproductive endocrinology research
• Oestrogen receptor competitive inhibition demonstrated at hypothalamic and pituitary tissue sites across multiple in vivo models
• Differential isomer activity – enclomiphene demonstrates stronger hypothalamic antagonism and shorter half-life relative to zuclomiphene in pharmacokinetic studies

Research Applications

• Hypothalamic-pituitary-gonadal (HPG) axis modulation studies
• Male hypogonadism and gonadotropin-dependent testosterone regulation research
• Reproductive endocrinology and ovulation induction models
• SERM pharmacology and oestrogen receptor binding studies
• Comparative SERM research (Clomiphene vs Tamoxifen receptor profiles)
• Spermatogenesis and male fertility research models

Studies & Additional Information

Clomiphene Citrate has an extensive research history spanning reproductive medicine, endocrinology, and male hormonal health. It has been studied across clinical trials examining its role in male hypogonadism as an alternative to exogenous testosterone therapy, with published findings in journals including the Journal of Urology and Fertility and Sterility.

More recent research has focused on enclomiphene citrate, the trans isomer, as a pharmacologically distinct compound with potential advantages in testosterone restoration without suppression of spermatogenesis, making it an area of active investigation in male reproductive endocrinology.

Disclaimer: Clomiphene Citrate is supplied strictly for laboratory research purposes. It is not intended for human consumption, therapeutic use, or self-administration. All research involving this compound should be conducted by qualified personnel in an appropriate laboratory setting and in accordance with applicable regulations.

Frequently Asked Questions

What is Clomiphene Citrate classified as?

Clomiphene Citrate is a selective oestrogen receptor modulator (SERM). It competitively binds to oestrogen receptors in the hypothalamus and pituitary, blocking negative feedback and stimulating gonadotropin secretion.

How does Clomiphene Citrate affect the HPG axis?

By blocking hypothalamic oestrogen receptors, Clomiphene Citrate removes the negative feedback signal that suppresses GnRH release. This leads to increased LH and FSH secretion from the pituitary, which in turn stimulates gonadal hormone production.

What is the difference between enclomiphene and zuclomiphene?

Clomiphene Citrate is a racemic mixture of two isomers. Enclomiphene (trans isomer) is the more potent oestrogen receptor antagonist with a shorter half-life. Zuclomiphene (cis isomer) has weaker antagonist activity and a significantly longer half-life, accumulating with repeated exposure.

How does Clomiphene Citrate differ from Tamoxifen (Nolvadex) as a SERM?

Both compounds are SERMs that act on oestrogen receptors, but they differ in tissue selectivity and receptor binding profiles. Clomiphene Citrate exerts its primary effects at the hypothalamic-pituitary level, driving gonadotropin release. Tamoxifen has broader tissue receptor activity and is more extensively studied in breast tissue models. Their distinct profiles make them subjects of comparative SERM pharmacology research.

What research areas is Clomiphene Citrate most investigated in?

The primary research areas include reproductive endocrinology, HPG axis modulation, male hypogonadism, and ovulation induction in anovulatory models. Emerging research focuses on enclomiphene specifically as a selective agent for testosterone restoration in male subjects.